Summit to focus on clinical assets as workforce halved
This article was originally published in Scrip
Executive Summary
UK drug discovery company Summit said it has updated its corporate strategy to focus on the development of clinical stage programmes targeting Duchenne Muscular Dystrophy (DMD) and Clostridium difficile infections while "curtailing" internal discovery stage research.